000 01949 a2200529 4500
005 20250513160613.0
264 0 _c19990301
008 199903s 0 0 eng d
022 _a0027-8424
024 7 _a10.1073/pnas.96.1.133
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aFisher, J E
245 0 0 _aAlendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
_h[electronic resource]
260 _bProceedings of the National Academy of Sciences of the United States of America
_cJan 1999
300 _a133-8 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAlendronate
_xpharmacology
650 0 4 _aAnimals
650 0 4 _aBone Resorption
_xmetabolism
650 0 4 _aCell Differentiation
_xdrug effects
650 0 4 _aCells, Cultured
650 0 4 _aCholesterol
_xbiosynthesis
650 0 4 _aClodronic Acid
_xpharmacology
650 0 4 _aDiterpenes
_xpharmacology
650 0 4 _aEnzyme Activation
_xdrug effects
650 0 4 _aFarnesol
_xpharmacology
650 0 4 _aHydroxymethylglutaryl-CoA Reductase Inhibitors
_xpharmacology
650 0 4 _aLovastatin
_xpharmacology
650 0 4 _aMevalonic Acid
_xmetabolism
650 0 4 _aMice
650 0 4 _aOsteoclasts
_xcytology
650 0 4 _aProtein Kinases
_xmetabolism
650 0 4 _aRabbits
650 0 4 _aSkull
_xmetabolism
650 0 4 _aSqualene
_xpharmacology
700 1 _aRogers, M J
700 1 _aHalasy, J M
700 1 _aLuckman, S P
700 1 _aHughes, D E
700 1 _aMasarachia, P J
700 1 _aWesolowski, G
700 1 _aRussell, R G
700 1 _aRodan, G A
700 1 _aReszka, A A
773 0 _tProceedings of the National Academy of Sciences of the United States of America
_gvol. 96
_gno. 1
_gp. 133-8
856 4 0 _uhttps://doi.org/10.1073/pnas.96.1.133
_zAvailable from publisher's website
999 _c9837167
_d9837167